- Home
- HHH vs RYTM Comparison
HHH vs RYTM Comparison
Compare HHH & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHH
- RYTM
- Stock Information
- Founded
- HHH 2010
- RYTM 2008
- Country
- HHH United States
- RYTM United States
- Employees
- HHH N/A
- RYTM N/A
- Industry
- HHH Real Estate Investment Trusts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HHH Real Estate
- RYTM Health Care
- Exchange
- HHH Nasdaq
- RYTM Nasdaq
- Market Cap
- HHH 3.3B
- RYTM 3.8B
- IPO Year
- HHH N/A
- RYTM 2017
- Fundamental
- Price
- HHH $68.08
- RYTM $65.67
- Analyst Decision
- HHH Strong Buy
- RYTM Strong Buy
- Analyst Count
- HHH 3
- RYTM 12
- Target Price
- HHH $82.33
- RYTM $76.75
- AVG Volume (30 Days)
- HHH 725.6K
- RYTM 628.6K
- Earning Date
- HHH 05-07-2025
- RYTM 05-07-2025
- Dividend Yield
- HHH 5.14%
- RYTM N/A
- EPS Growth
- HHH N/A
- RYTM N/A
- EPS
- HHH 5.22
- RYTM N/A
- Revenue
- HHH $1,793,533,000.00
- RYTM $136,863,000.00
- Revenue This Year
- HHH N/A
- RYTM $37.88
- Revenue Next Year
- HHH $24.62
- RYTM $72.84
- P/E Ratio
- HHH $13.03
- RYTM N/A
- Revenue Growth
- HHH 106.40
- RYTM 48.88
- 52 Week Low
- HHH $59.83
- RYTM $36.27
- 52 Week High
- HHH $87.77
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HHH 47.19
- RYTM 60.86
- Support Level
- HHH $65.87
- RYTM $58.72
- Resistance Level
- HHH $69.58
- RYTM $63.24
- Average True Range (ATR)
- HHH 1.25
- RYTM 2.47
- MACD
- HHH -0.12
- RYTM 0.26
- Stochastic Oscillator
- HHH 36.57
- RYTM 98.06
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.